ERBB2 and gastric cancer: After restricting the analysis to immunotherapy agents with global regulatory approval for the 1L treatment of HER2-negative GC/GEJC, in addition to tislelizumab + CT, five trials remained for the base case analysis (see Online Resource 2 for details).